ProPhase Net Income Applicable To Common Shares from 2010 to 2024
| PRPH Stock | USD 0.74 0.03 3.90% |
Net Income Applicable To Common Shares | First Reported 2000-03-31 | Previous Quarter 550 K | Current Value -3.4 M | Quarterly Volatility 5 M |
Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Selling General Administrative of 32.8 M or Total Revenue of 35.5 M, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.067 or PTB Ratio of 1.5. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
ProPhase | Net Income Applicable To Common Shares |
Latest ProPhase Labs' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of ProPhase Labs over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. ProPhase Labs' Net Income Applicable To Common Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProPhase Labs' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
ProPhase Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | 2,895,373 | |
| Geometric Mean | 3,079,465 | |
| Coefficient Of Variation | 393.64 | |
| Mean Deviation | 7,126,231 | |
| Median | (1,091,000) | |
| Standard Deviation | 11,397,303 | |
| Sample Variance | 129.9T | |
| Range | 48.4M | |
| R-Value | 0.27 | |
| Mean Square Error | 129.9T | |
| R-Squared | 0.07 | |
| Significance | 0.34 | |
| Slope | 680,390 | |
| Total Sum of Squares | 1818.6T |
ProPhase Net Income Applicable To Common Shares History
About ProPhase Labs Financial Statements
Investors use fundamental indicators, such as ProPhase Labs' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 7.2 M | 7.6 M |
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out the analysis of ProPhase Labs Correlation against competitors. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share 0.996 | Quarterly Revenue Growth (0.81) | Return On Assets (0.23) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.